Overcoming Resistance to Immunotherapy combining Gemcitabine with atezolizumab in advanced NSCLC and mesothelioma progressINg under immune-checkpoint inhibitors or gemcitabine. A multicenter, single-arm, open label phase II trial with two cohort.

Projekt

Overcoming Resistance to Immunotherapy combining Gemcitabine with atezolizumab in advanced NSCLC and mesothelioma progressINg under immune-checkpoint inhibitors or gemcitabine. A multicenter, single-arm, open label phase II trial with two cohort.

Abgeschlossen · 2021 bis 2024

Jörger Markus, Scherrer Julia, Quinter Janine

Art

Klinische Forschung

Reichweite

Multizentrisch, KSSG als teilnehmendes Zentrum

Bereiche

Medizinische Onkologie und Hämatologie

Status

Abgeschlossen

Start

2021

Ende

2024

Finanzierungsart

SAKK

Studiendesign

Phase II

Schlagwörter (Tags)

Immunotherapy combining Gemcitabine with atezolizumab, advanced NSCLC, mesothelioma progressing, immune-checkpoint inhibitors or gemcitabine

Label

Lungenkrebs

Kurzbeschreibung/Zielsetzung

A significant number of patients with malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) are not cured with available treatments and will eventually relapse. After relapse treatment options are limited. Preclinical in vitro studies have demon-strated a synergism of immunotherapy with PD(L)1- targeting monoclonal antibodies and gemcitabine ad-ministered in different tumors models and ongoing clin-ical studies showed encouraging results. This may represent a safe and effective therapy for patients who relapsed or did not respond to standard therapies.